You are here
Home > Anamorelin

Helsinn initiates two new global Phase III studies with anamorelin

Helsinn initiates two new global Phase III studies with anamorelin Helsinn committed to anamorelin which is being evaluated for weight loss and anorexia in patients with advanced non small cell lung cancer (NSCLC) and cachexia ONO has submitted application for manufacturing and marketing approval of anamorelin in Japan LUGANO, Switzerland, March 7, 2019: Helsinn Group, […]

Top